TRexBio raises $116.7M in Nasdaq IPO at $14 per share
TRexBio (Nasdaq: TRXB) raised $116.7M in its IPO at $14 per share, selling 8.3M shares. The biotech firm focuses on autoimmune and inflammatory disease treatments. J.P. Morgan and others managed the offering, effective Oct. 8, 2026.
How this was made
The 30-second read
Why it matters
The disclosed IPO size and $14 offer price provide the key inputs for positioning around the listing, including initial valuation framing and expected liquidity.
Market read
Traders can use the offer price, share count, and gross proceeds to gauge IPO supply and set expectations for early trading behavior.
What to watch
First-day float, lock-up terms, and any concurrent sell-side research coverage are not covered here, yet they often dominate near-term IPO price action.
Background
TRexBio is a clinical-stage biotech developing immunoregulatory medicines targeting autoimmune and inflammatory diseases via tissue regulatory T cell biology.
Ticker impact
TRexBio priced and closed its Nasdaq IPO, selling 8,333,334 shares at $14 for about $116.7M gross proceeds.
Likely initial volatility with upward bias if demand was strong, but direction will depend on first-day pricing versus the $14 offer.
The article discloses the offer price, share count, and gross proceeds, which are primary IPO mechanics that can drive early order-flow and sentiment.
Market effects
Adds a new clinical-stage biotech listing focused on immunoregulatory T cell biology, which can marginally affect IPO sentiment in the biotech pipeline.
Limited broader regional impact; primarily affects Nasdaq small-cap/IPO flow.
Low global relevance beyond biotech IPO appetite and risk sentiment.
Counterpoint
IPO proceeds and offer price do not guarantee post-listing performance; early trading can fade if valuation or demand expectations were overstated.
Key entities
- companyTRex Bio, Inc.
Clinical-stage biotech that raised about $116.7M gross in its Nasdaq IPO at $14 per share.
- venueNasdaq
Exchange where TRexBio’s shares are listed under ticker TRXB.
- financial_institutionsJ.P. Morgan, Evercore ISI, Cantor, Stifel
Lead book-running managers for the IPO.
